**Supplementary Material**

|  |
| --- |
| Supplementary Table 1. Demographic and clinical characteristics of patients admitted from a post-acute care facility and screened for carbapenem-resistant *A. baumannii*. |
|   | **Total****151 (%)** | **Carbapenem-resistant *A. baumannii* positive****14 (%)** | **Carbapenem-resistant *A. baumannii* negative****137 (%)** | **P value** |
| **Age (years) median, SD** | 66.2, 15.4 | 55,13 | 67,15 | 0.003 |
| **Male** | 78 (51.7) | 7 (50) | 71 (51.8) | 0.896 |
| **Race** |  |  |  |  |
| White | 76 (50.3) | 4 (28.6) | 72 (52.6) | 0.100 |
| African-American | 69 (45.7) | 10 (71.4) | 59 (43.1) | 0.042 |
| Asian  | 4 (2.6) | 0 | 4 (2.9) | - |
| Other | 2 (1.3) | 0 | 2 (1.5) | - |
| **Ethnicity** |  |  |  |  |
| Non-Hispanic | 149 (98.7) | 14 (100) | 135 (98.5) | - |
| Hispanic | 2 (1.3) | 0 | 2 (1.5) | 1 |
| **Ventilator dependent** | 29 (19.2) | 10 (71.4) | 19 (13.9) | <0.001 |
| **Foley-catheter** | 30 (19.9) | 9 (64.3) | 21 (15.3) | <0.001 |
| **Feeding tube** | 46 (30.5) | 11 (78.6) | 35 (25.5) | <0.001 |
| **Tracheostomy/not ventilator dependent** | 7 (8.6) | 1 (7.1) | 6 (4.4) | 0.501 |
| **Any other invasive devices** | 3 (2) | 0 | 3 (2.2) | - |
| **Chronic wound** | 23 (15.2) | 6 (42.9) | 17 (12.4) | 0.003 |
| **Prior hospitalization in the past 30 days** | 36 (23.8) | 7 (50) | 29 (21.2) | 0.016 |
| **Prior surgery in the past 30-days** | 9 (6) | 0 | 9 (6.6) | - |
| **Dialysis** | 7 (4.6) | 0 | 7 (5.1) | - |
| **Length of stay in the first hospitalization (days) median, IQR** | 11, 5-21.3 | 6, 4-13 | 11, 6-22 | 0.035 |
| **Comorbidities** |  |  |  |  |
| Myocardial infarction | 8 (5.3) | 2 (14.3) | 6 (4.4) | 0.162 |
| Congestive heart failure | 23 (15.2) | 2 (14.3) | 21 (15.3) | 1 |
| Peripheral vascular disease | 21 (13.9) | 2 (14.3) | 19 (13.9) | 1 |
| CVA/TIA | 36 (23.8) | 2 (14.3) | 34 (24.8) | 0.520 |
| Dementia | 23 (15.2) | 1 (7.1) | 22 (16.1) | 0.696 |
| Chronic obstructive pulmonary disease | 34 (22.5) | 3 (21.4) | 31 (22.6) | 1 |
| Connective tissue disease | 8 (5.3) | 1 (7.1) | 7 (5.1) | 0.550 |
| Peptic ulcer disease | 13 (8.6) | 2 (14.3) | 11 (8) | 0.345 |
| Liver disease | 6 (4) | 0 | 6 (4.4) | - |
| DM with end organ damage | 21 (13.9) | 2 (14.3) | 19 (13.9) | 1 |
| DM without end organ damage | 31 (20.5) | 5 (35.7) | 26 (19) | 0.165 |
| Hemiplegia | 8 (5.3) | 0 | 8 (5.8) | - |
| Quadriplegia | 12 (7.9) | 5 (35.7) | 7 (5.1) | <0.001 |
| Renal disease | 42 (27.8) | 0 | 42 (30.7) | - |
| Solid tumor | 27 (17.9) | 2 (14.3) | 25 (18.2) | 1 |
| Leukemia | 1 (0.7) | 0 | 7 (0.7) | - |
| Multiple myeloma | 3 (2) | 0 | 3 (2.2) | - |
| Acquired immunodeficiency syndrome | 1 (0.7) | 0 | 7 (0.7) | - |

SD: Standard deviation. IQR: Interquartile range. CVA/TIA: Cerebrovascular accident/Transient ischemic attack. DM: Diabetes mellitus. \*p<0.05.

Supplementary Figure 1.

Title: Epidemic curve of patients positive for carbapenem-resistant *Acinetobacter baumannii.*

Legend: \*Surveillance cultures started on December 2018. Blue bars show patients admitted from post-acute care facilities. Pink bars show patients admitted from their private residency. White dots show patients positive for OXA-24/40-like β-lactamase OXA-72.